Synaptosomal bioenergetic defects are associated with cognitive impairment in a transgenic rat model of early Alzheimer's disease

Journal of Cerebral Blood Flow and Metabolism

Volumn 37, Issue 1, 2017, Pages 69-84

  Adami, Pamela V Martino ^a   Quijano, Celia ^b   Magnani, Natalia ^c   Galeano, Pablo ^a,c   Evelson, Pablo ^c   Cassina, Adriana ^b   Do Carmo, Sonia ^d   Leal, María C ^a   Castaño, Eduardo M ^a   Cuello, A Claudio ^d   Morelli, Laura ^a  

^a FUNDACIÓN INSTITUTO LELOIR   (Argentina)

^b DEPARTAMENTO DE BIOQUÍMICA   (Uruguay)

^c UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

Amyloid ; early Alzheimer; hippocampal bioenergetics status; neurodegeneration; synaptosomes

Indexed keywords

REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); PYRROLOQUINOLINEQUINONE;

AEROBIC METABOLISM; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; BIOENERGY; BRAIN HOMOGENATE; BRAIN MITOCHONDRION; CELL FRACTIONATION; CELL ISOLATION; COGNITIVE DEFECT; COMPARATIVE STUDY; CONTROLLED STUDY; DIET; DISEASE ASSOCIATION; ENERGY METABOLISM; ENZYME ACTIVITY; EXPLORATORY BEHAVIOR; HUMAN; IN VIVO STUDY; MICRODISSECTION; MITOCHONDRIAL BIOGENESIS; MITOCHONDRIAL RESPIRATION; NEUROPROTECTION; NONHUMAN; OXYGEN CONSUMPTION; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; RAT; RESPIRATION CONTROL; SYNAPTOSOME; TRANSMISSION ELECTRON MICROSCOPY; WEANING; ANIMAL; COGNITIVE DYSFUNCTION; DIET THERAPY; DISEASE MODEL; METABOLISM; MITOCHONDRION; PATHOLOGY; TRANSGENIC RAT;

ALZHEIMER DISEASE; ANIMALS; COGNITIVE DYSFUNCTION; DIET THERAPY; DISEASE MODELS, ANIMAL; ELECTRON TRANSPORT COMPLEX I; ENERGY METABOLISM; MITOCHONDRIA; PQQ COFACTOR; RATS; RATS, TRANSGENIC; SYNAPTOSOMES;

EID: 85006386958     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1177/0271678X15615132     Document Type: Article

References (53)

1. Hardy J and Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 1991; 12(10): 383-388.
2. Adriaanse SM, Binnewijzend MA, Ossenkoppele R, et al. Widespread disruption of functional brain organization in early-onset Alzheimer's disease. PLoS One 2014; 9: e102995.
3. Rapoport SI, Hatanpaa K, Brady DR, et al. Brain energy metabolism, cognitive function and down-regulated oxi-dative phosphorylation in Alzheimer disease. Neurodegeneration: A journal for neurodegenerative dis-orders, neuroprotection, and neuroregeneration 1996; 5: 473-476.
4. Liang WS, Reiman EM, Valla J, et al. Alzheimer's disease is associated with reduced expression of energy metabolism genes in posterior cingulate neurons. Proc Natl Acad Sci USA 2008; 105: 4441-4446.
5. Keil U, Bonert A, Marques CA, et al. Amyloid beta-induced changes in nitric oxide production and mito-chondrial activity lead to apoptosis. J Biol Chem 2004; 279: 50310-50320.
6. Swerdlow RH and Khan SM. A "mitochondrial cascade hypothesis" for sporadic Alzheimer's disease. Med Hypotheses 2004; 63: 8-20.
7. Leal MC, Magnani N, Villordo S, et al. Transcriptional regulation of insulin-degrading enzyme modulates mito-chondrial amyloid beta (Abeta) peptide catabolism and functionality. J Biol Chem 2013; 288: 12920-12931.
8. Killgore J, Smidt C, Duich L, et al. Nutritional importance of pyrroloquinoline quinone. Science 1989; 245: 850-852.
9. Smidt CR, Unkefer CJ, Houck DR, et al. Intestinal absorption and tissue distribution of [14C]pyrroloquinoline quinone in mice. Proc Soc Exp Biol Med 1991; 197: 27-31.
10. Jensen FE, Gardner GJ, Williams AP, et al. The putative essential nutrient pyrroloquinoline quinone is neuropro-tective in a rodent model of hypoxic/ischemic brain injury. Neuroscience 1994; 62: 399-406.
11. Trushina E, Nemutlu E, Zhang S, et al. Defects in mito-chondrial dynamics and metabolomic signatures of evolving energetic stress in mouse models of familial Alzheimer's disease. PLoS One 2012; 7: e32737.
12. Balietti M, Giorgetti B, Casoli T, et al. Early selective vulnerability of synapses and synaptic mitochondria in the hippocampal CA1 region of the Tg2576 mouse model of Alzheimer's disease. J Alzheimers Dis 2013; 34: 887-896.
13. Choi SW, Gerencser AA, Ng R, et al. No consistent bio-energetic defects in presynaptic nerve terminals isolated from mouse models of Alzheimer's disease. J Neurosci 2012; 32: 16775-16784.
14. Leon WC, Canneva F, Partridge V, et al. A novel trans-genic rat model with a full Alzheimer's-like amyloid pathology displays pre-plaque intracellular amyloid-beta-associated cognitive impairment. J Alzheimers Dis 2010; 20: 113-126.
15. Galeano P, Martino Adami PV, Do Carmo S, et al. Longitudinal analysis of the behavioral phenotype in a novel transgenic rat model of early stages of Alzheimer's disease. Front Behav Neurosci 2014; 8: 321.
16. Bauerly K, Harris C, Chowanadisai W, et al. Altering pyrroloquinoline quinone nutritional status modulates mitochondrial, lipid, and energy metabolism in rats. PLoS One 2011; 6: e21779.
17. Cadenas E and Boveris A. Enhancement of hydrogen peroxide formation by protophores and ionophores in antimycin-supplemented mitochondria. Biochem J 1980; 188: 31-37.
18. Boveris A, Costa LE, Cadenas E, et al. Regulation of mitochondrial respiration by adenosine diphosphate, oxygen, and nitric oxide. Methods Enzymol 1999; 301: 188-198.
19. Boveris A. Determination of the production of super-oxide radicals and hydrogen peroxide in mitochondria. Methods Enzymol 1984; 105: 429-435.
20. Yagi K. A simple fluorometric assay for lipoperoxide in blood plasma. Biochem Med 1976; 15: 212-216.
21. Brand MD and Nicholls DG. Assessing mitochondrial dysfunction in cells. Biochem J 2011; 435: 297-312.
22. Kauppinen RA and Nicholls DG. Synaptosomal bioener-getics. The role of glycolysis, pyruvate oxidation and responses to hypoglycaemia. Eur J Biochem 1986; 158: 159-165.
23. Choi SW, Gerencser AA and Nicholls DG. Bioenergetic analysis of isolated cerebrocortical nerve terminals on a microgram scale: spare respiratory capacity and stochastic mitochondrial failure. J Neurochem 2009; 109: 1179-1191.
24. Papa S, Francavilla A, Paradies G, et al. The transport of pyruvate in rat liver mitochondria. FEBS Lett 1971; 12: 285-288.
25. Reddy PH and Beal MF. Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. Trends Mol Med 2008; 14: 45-53.
26. Wu JJ, Quijano C, Chen E, et al. Mitochondrial dysfunction and oxidative stress mediate the physiological impairment induced by the disruption of autophagy. Aging 2009; 1: 425-437.
27. Tsukada H. The use of (1)(8)F-BCPP-EF as a PET probe for complex I activity in the brain. Methods Enzymol 2014; 547: 417-431.
28. Gibson GE, Sheu KF, Blass JP, et al. Reduced activities of thiamine-dependent enzymes in the brains and peripheral tissues of patients with Alzheimer's disease. Arch Neurol 1988; 45: 836-840.
29. Almeida CG, Tampellini D, Takahashi RH, et al. Beta-amyloid accumulation in APP mutant neurons reduces PSD-95 and GluR1 in synapses. Neurobiol Dis 2005; 20: 187-198.
30. Perez-Nievas BG, Stein TD, Tai HC, et al. Dissecting phenotypic traits linked to human resilience to Alzheimer's pathology. Brain 2013; 136: 2510-2526.
31. Ohwada K, Takeda H, Yamazaki M, et al. Pyrroloquinoline Quinone (PQQ) Prevents Cognitive Deficit Caused by Oxidative Stress in Rats. J Clin Biochem Nutr 2008; 42: 29-34.
32. Whishaw IQ, Metz GA, Kolb B, et al. Accelerated nervous system development contributes to behavioral efficiency in the laboratory mouse: A behavioral review and theoretical proposal. Dev Psychobiol 2001; 39: 151-170.
33. Do Carmo S and Cuello AC. Modeling Alzheimer's disease in transgenic rats. Mol Neurodegener 2013; 8: 37.
34. Carreras MC, Franco MC, Peralta JG, et al. Nitric oxide, complex I, and the modulation of mitochondrial reactive species in biology and disease. Molecul Aspect Med 2004; 25: 125-139.
35. Moreno-Lastres D, Fontanesi F, Garcia-Consuegra I, et al. Mitochondrial complex I plays an essential role in human respirasome assembly. Cell Metab 2012; 15: 324-335.
36. Gabbita SP, Lovell MA and Markesbery WR. Increased nuclear DNA oxidation in the brain in Alzheimer's disease. J Neurochem 1998; 71: 2034-2040.
37. Halliwell B and Dizdaroglu M. The measurement of oxi-dative damage to DNA by HPLC and GC/MS tech-niques. Free Radical Res Commun 1992; 16: 75-87.
38. Nicholls DG. Oxidative stress and energy crises in neur-onal dysfunction. Ann N Y Acad Sci 2008; 1147: 53-60.
39. Bolanos JP, Almeida A and Moncada S. Glycolysis: a bioenergetic or a survival pathway? Trends Biochem Sci 2010; 35: 145-149.
40. Soucek T, Cumming R, Dargusch R, et al. The regulation of glucose metabolism by HIF-1 mediates a neuroprotec-tive response to amyloid beta peptide. Neuron 2003; 39: 43-56.
41. Chandrasekaran K, Hatanpaa K, Brady DR, et al. Evidence for physiological down-regulation of brain oxi-dative phosphorylation in Alzheimer's disease. Exp Neurol 1996; 142: 80-88.
42. Dumont M, Ho DJ, Calingasan NY, et al. Mitochondrial dihydrolipoyl succinyltransferase deficiency accelerates amyloid pathology and memory deficit in a transgenic mouse model of amyloid deposition. Free Radic Biol Med 2009; 47: 1019-1027.
43. Austin S and St-Pierre J. PGC1alpha and mitochondrial metabolism-emerging concepts and relevance in ageing and neurodegenerative disorders. J Cell Sci 2012; 125: 4963-4971.
44. Scheff SW, Neltner JH and Nelson PT. Is synaptic loss a unique hallmark of Alzheimer's disease?. Biochem Pharmacol 2014; 88: 517-528.
45. Pathak D, Shields LY, Mendelsohn BA, et al. The role of mitochondrially derived ATP in synaptic vesicle recycling. J Biol Chem 2015; 290: 22325-22336.
46. Murthy VN and De Camilli P. Cell biology of the pre-synaptic terminal. Annu Rev Neurosci 2003; 26: 701-728.
47. Tu S, Okamoto S, Lipton SA, et al. Oligomeric Abeta-induced synaptic dysfunction in Alzheimer's disease. Mol Neurodegener 2014; 9: 48.
48. Qi Y, Klyubin I, Harney SC, et al. Longitudinal testing of hippocampal plasticity reveals the onset and maintenance of endogenous human Ass-induced synaptic dysfunction in individual freely behaving pre-plaque transgenic rats: Rapid reversal by anti-Ass agents. Acta Neuropathologica Commun 2014; 2: 175.
49. Merlini M, Meyer EP, Ulmann-Schuler A, et al. Vascular beta-amyloid and early astrocyte alterations impair cere-brovascular function and cerebral metabolism in trans-genic arcAbeta mice. Acta Neuropathol 2011; 122: 293-311.
50. Winkler EA, Nishida Y, Sagare AP, et al. GLUT1 reductions exacerbate Alzheimer's disease vasculo-neuronal dysfunction and degeneration. Nat Neurosci 2015; 18: 521-530.
51. Takatsu H, Owada K, Abe K, et al. Effect of vitamin E on learning and memory deficit in aged rats. J Nutr Sci Vitaminol 2009; 55: 389-393.
52. Zhao L, Gong N, Liu M, et al. Beneficial synergistic effects of microdose lithium with pyrroloquinoline quin-one in an Alzheimer's disease mouse model. Neurobiol Aging 2014; 35: 2736-2745.
53. Aizenman E, Hartnett KA, Zhong C, et al. Interaction of the putative essential nutrient pyrroloquinoline quinone with the N-methyl-D-aspartate receptor redox modula-tory site. J Neurosci 1992; 12: 2362-2369.